MF
SUPN icon

Magnetar Financial’s Supernus Pharmaceuticals SUPN Stock Holding History

Magnetar Financial’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$352K Buy
7,561
+2,680
+55% +$129K ﹤0.01% 720
2026
Q1 		$252K Buy
+4,881
New +$249K ﹤0.01% 817

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Magnetar Financial's SUPN Position: Q2 2026 in Review

Magnetar Financial increased its Supernus Pharmaceuticals (SUPN) stake by 55% in Q2 2026, buying an estimated $129K and bringing the position to 7,561 shares worth $352K. The position accounts for ﹤0.01% of the portfolio, ranked #720.

Magnetar Financial first reported a position in SUPN in Q1 2026 and has held it in 2 quarters since. 335 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Magnetar Financial held 7,561 shares of Supernus Pharmaceuticals worth $352K as of Q2 2026.
  • Magnetar Financial bought 2,680 Supernus Pharmaceuticals shares in Q2 2026, an estimated $129K.
  • Supernus Pharmaceuticals made up ﹤0.01% of Magnetar Financial's portfolio in Q2 2026, its #720 holding.
  • Magnetar Financial first reported a position in Supernus Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 335 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Magnetar Financial's 13F filing for Q2 2026, filed 14 Aug 2026.